研究单位：[1]Biogen[2]Beijing Hospital,Beijing,China,100730[3]Xiangya Hospital Central South University,Changsha,China,410008[4]West China Hospital of Sichuan University,Chengdu City,China,610041[5]The First Affiliated Hospital of Fujian Medical University,Fuzhou,China,350005[6]Nanfang Hospital, Southern Medical University,Guangzhou,China,510515[7]The Third Affiliated Hospital of Sun Yat-Sen University,Guangzhou,China,510630[8]The First Affiliated Hospital of Zhejiang University school,Hangzhou,China,310003[9]The Second Hospital of Hebei Medical University,Hebei,China,050004[10]The First People's Hospital of Yunnan Province,Kunming,China,650032[11]Renji Hospital, Shanghai Jiatong Uni. School of Medicine,Shanghai,China,200001[12]Huashan Hospital, Fudan University,Shanghai,China,200040[13]The First Hospital of China Medical University,Shengyang,China,110002[14]The First Affiliated Hospital of Soochow University,Suzhou,China,215004[15]The First Affiliated Hospital of Shanxi Medical University,Taiyuan,China,30001[16]Tianjin Medical University General Hospital,Tianjin,China,300052[17]The First Affiliated Hospital of Wenzhou Medical University,Wenzhou,China,325000[18]Second Affiliated Hospital of Air Force Medical University,Xi'An,China,710038
研究目的：
The primary objective of the study is to assess the efficacy of DMF in Chinese participants with RMS at Week 48. The secondary objectives of the study are to assess the efficacy and safety of DMF in Chinese participants with RMS.
